Inozyme Pharma (INZY)
(Real Time Quote from BATS)
$4.46 USD
+0.02 (0.45%)
Updated Apr 29, 2024 01:40 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
INZY 4.46 +0.02(0.45%)
Will INZY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INZY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INZY
Inozyme Pharma, Inc. (INZY) Moves to Buy: Rationale Behind the Upgrade
Why Earnings Season Could Be Great for Inozyme (INZY)
INZY: What are Zacks experts saying now?
Zacks Private Portfolio Services
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
Sorrento (SRNE) Up on Positive Result From Lung Cancer Study
bluebird (BLUE) Up 101% in the Past Three Months: Here's Why
Other News for INZY
Inozyme management to meet with Piper Sandler
Inozyme management to meet with Piper Sandler
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Inozyme price target lowered by $2 at BofA, here's why
Analysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)